Danish drugmaker Novo Nordisk said Friday it would invest 42 billion kroner ($6 billion) to expand manufacturing facilities in efforts to meet massive demand for its anti-diabetes and anti-obesity treatments.
Nov 10, 2023
0
0
The U.S. Food and Drug Administration has received at least three reports of people being hospitalized after taking counterfeit versions of the wildly popular weight-loss drugs known as semaglutides.
Nov 8, 2023
0
0
Danish drugmaker Novo Nordisk reported Thursday a sharp rise in third quarter sales and profits driven by the success of its anti-diabetes and anti-obesity treatments Ozempic and Wegovy.
Nov 2, 2023
0
0
Ozempic, a type 2 diabetes drug that has increasingly been used to help with weight loss, will now be labeled as having the potential to block intestines.
Sep 28, 2023
0
5
Another diabetes drug maker is taking legal action against businesses in several states, alleging that they're "fraudulently claiming" that their compounded products are the same as its medication.
Sep 21, 2023
0
1
Health care professionals and organizations need to respond more forcefully to unethical marketing from the pharmaceutical industry by holding offending companies to greater account and by supporting stronger regulation, ...
Sep 19, 2023
1
79
In February 2021, The Conversation reported on a trial for a new weight-loss drug, called semaglutide, that was being hailed in the media as a "gamechanger." Gamechanger is a word used far too often by journalists to describe ...
Sep 6, 2023
0
1
Patients with hemophilia A or B with inhibitors have a lower annualized bleeding rate with concizumab than with no prophylaxis, according to a phase 3 study published online Aug. 31 in the New England Journal of Medicine.
Sep 3, 2023
0
1
Our pancreas has different cells that do important jobs to control our blood sugar. One of the genes in pancreatic cells is called Neurogenin 3 (NEUROG3). Its mutation can lead to diabetes. It is active only for a short period ...
Aug 31, 2023
0
31
As demand for the wildly popular weight-loss drug Wegovy continues to climb, drug maker Novo Nordisk said Thursday that it will continue restrictions on starter doses of the medication into 2024. The new plan extends by months ...
Aug 14, 2023
0
23
